Study overview and purpose
This observational study evaluated whether the combined use of glucagon-like peptide-1 receptor agonists (GLP-1s) and adherence to multiple healthy lifestyle habits was associated with a lower risk of cardiovascular events in people living with type 2 diabetes. Investigators grouped participants according to two exposures — GLP-1 medication use and the degree of adherence to a set of predefined healthy behaviors — and compared rates of major cardiovascular outcomes, including heart attack and stroke, across those groups. The work was published in medichelpline and received funding from the Department of Veteran Affairs. By examining real-world patterns of treatment and behavior, the study sought to clarify how pharmacologic therapy and lifestyle factors relate to cardiovascular risk among people with diabetes.
How GLP-1 medications act in the body
GLP-1 receptor agonists are a class of medications that mimic the naturally occurring hormone glucagon-like peptide-1. The hormone has several physiologic roles relevant to metabolic health: it supports regulation of blood glucose, slows gastric emptying, and promotes a sense of fullness after eating. GLP-1 medications harness these mechanisms in clinical care to improve glycemic control and to assist with weight management. In this study context, investigators considered GLP-1 use as one of the exposures potentially linked to cardiovascular outcomes in people with type 2 diabetes.
Clinical uses emphasized by the study
Within routine clinical practice, GLP-1 medications are commonly prescribed for management of type 2 diabetes and are increasingly used to support weight reduction when appropriate. The study framed GLP-1 use alongside lifestyle measures, reflecting how these medications are typically offered in combination with counseling about diet, physical activity, and other behavioral factors.
Healthy lifestyle habits evaluated
The research assessed participants’ adherence to a set of healthy behaviors and used that composite adherence as a second primary exposure. Examples of the lifestyle measures considered in the analysis included maintaining a healthy diet, engaging in regular physical activity, and avoiding tobacco use. Investigators categorized participants by how many of those healthy habits they followed; key comparisons were made between participants who adhered to six to eight healthy habits and those who followed three or fewer.
Key findings: combined and independent associations
The principal result reported by the investigators was a robust association between combined GLP-1 use plus high adherence to healthy habits and a lower risk of cardiovascular events. Specifically, participants who both used a GLP-1 medication and adhered to six-to-eight healthy habits experienced a 43% lower risk of cardiovascular outcomes (such as heart attack and stroke) compared with participants who did not use a GLP-1 medication and who followed three or fewer healthy habits.
Beyond that combined association, the study also reported that GLP-1 use and high lifestyle adherence each showed associations with reduced cardiovascular risk independently. In other words, within the observational dataset, both being prescribed and using a GLP-1 medication and adhering to multiple healthy habits were individually associated with lower rates of cardiovascular events.
Why cardiovascular risk is a central concern for people with diabetes
Cardiovascular disease remains a leading cause of morbidity and mortality among people living with diabetes. Consistent with guidance from professional organizations, the study highlights that people with diabetes face an elevated risk of heart disease and stroke — approximately double the risk of those without diabetes, according to the American Diabetes Association. Given this substantially increased baseline risk, interventions that can lower cardiovascular events are a primary focus of diabetes management and research.
Clinical context: medication together with lifestyle counseling
In routine care, clinicians frequently combine pharmacologic treatment with behavioral counseling. When GLP-1 medications are prescribed, care teams commonly discuss dietary patterns, physical activity goals, smoking cessation, and other lifestyle behaviors that influence glycemic control, weight, and cardiovascular risk. The study’s findings reinforce the clinical principle that medication and lifestyle modification are complementary approaches: each can be associated with benefit, and their combination may correspond with greater reductions in risk than either strategy alone, at least as observed in this dataset.
Interpretation, strengths, and important limitations
Interpreting these results requires attention to the observational design. A key strength of observational research is its ability to capture treatment patterns and behaviors in real-world populations, which can provide insights beyond tightly controlled clinical trials. However, observational studies cannot establish causality with the same rigor as randomized controlled trials. Associations observed in the data — including the reported 43% lower risk for the combined exposure — describe relationships within the study population and should not be interpreted as definitive proof that the combination causes reduced cardiovascular events.
Another important limitation is the use of a composite measure of healthy habits. While composite adherence supports an integrated view of lifestyle, it does not isolate the specific contribution of any single behavior (for example, diet versus physical activity versus smoking cessation) to cardiovascular risk. The independent associations reported for GLP-1 use and for lifestyle adherence indicate both were linked to lower risk, but understanding the magnitude and mechanisms of their interaction across different patient subgroups will require additional study.
Implications for patients and clinicians
For clinicians and people living with type 2 diabetes, these findings underscore the potential value of addressing both pharmacologic and behavioral strategies when aiming to reduce cardiovascular risk. The study suggests that GLP-1 medications and adherence to multiple healthy lifestyle habits were each associated with lower rates of cardiovascular events in the observed population, and that their combination corresponded with a notably lower risk compared with low adherence and no GLP-1 use. Clinical decision-making should continue to be individualized: treatment discussions ought to consider a person’s overall risk profile, preferences, and goals, and should include shared decision-making about medications and achievable lifestyle changes.
Publication and funding transparency
The research was published in medichelpline and received funding support from the Department of Veteran Affairs. Reporting these details promotes transparency about the study’s provenance and the sources that supported the work.